2021 Year in Review - Renal-Cell Carcinoma

Over the past year, the COVID-19 pandemic has continued to affect the dissemination of critical clinical study findings.
In a phase 3 study, adjuvant pembrolizumab after nephrectomy improved disease-free survival versus placebo in patients with high-risk disease.
In a phase 3 trial, lenvatinib combined with pembrolizumab improved progression-free survival versus lenvatinib plus pembrolizumab or sunitinib and improved overall survival compared with sunitinib.
In a phase 3 trial, nivolumab combined with cabozantinib improved progression-free survival and overall survival versus sunitinib as first-line therapy.
Compared with sorafenib, tivozanib was associated with longer progression-free survival, higher rates of response, and better tolerability in the third-line setting and beyond.
In a phase 1b/2 study, lenvatinib plus pembrolizumab combination showed promise as first-line therapy and beyond.
In a phase 2 trial, atezolizumab plus bevacizumab showed promise after disease progression on monotherapy with atezolizumab or sunitinib.
The hypoxia-inducible factor-2α inhibitor belzutifan had antitumor activity in treatment-naïve and pretreated disease.
Combination therapy with cabozantinib and atezolizumab is associated with tolerability and antitumor activity across diverse renal-cell carcinoma histologies.
In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma.
Page 1 of 2
Results 1 - 10 of 19

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code